The present disclosure relates to a method for preventing, alleviating, improving or treating female hormone regulation disorder or symptoms, which contains a green tea extract with contents of ingredients changed. Specifically, the method according to an aspect of the present disclosure includes a step of administering an effective amount of a green tea extract, which contains (−)-gallocatechin gallate (GCG) and (−)-epigallocatechin gallate (EGCG) at specific contents, to a subject in need thereof, and may exhibit an effect of preventing, alleviating, improving or treating female hormone regulation disorder or symptoms.

The present disclosure relates to a method for preventing, alleviating, improving or treating female hormone regulation disorder or symptoms, which contains a green tea extract with contents of ingredients changed. Specifically, the method according to an aspect of the present disclosure includes a step of administering an effective amount of a green tea extract, which contains (−)-gallocatechin gallate (GCG) and (−)-epigallocatechin gallate (EGCG) at specific contents, to a subject in need thereof, and may exhibit an effect of preventing, alleviating, improving or treating female hormone regulation disorder or symptoms.

The present invention relates to a pharmaceutical composition for preventing or treating COVID-19 diseases, comprising an organic solvent extract of Justicia procumbens as an effective ingredient, a pharmaceutical composition for preventing or treating COVID-19 diseases, comprising justicidin-A as an effective ingredient, a pharmaceutical composition for preventing or treating COVID-19 diseases, comprising justicidin-B as an effective ingredient, or a pharmaceutical composition for preventing or treating COVID-19 diseases, comprising 6′ hydroxyl justicidin-B as an effective ingredient, and a food composition thereof for preventing or ameliorating COVID-19 diseases. According to the present invention, an anhydrous ethanol extract of Justicia procumbens, justicidin-A, justicidin-B, and 6′ hydroxyl justicidin-B effectively inhibit SARS-CoV-2 virus, and thus may effectively prevent, treat, or ameliorate diseases caused by SARS-CoV-2 virus.

The present invention relates to a pharmaceutical composition for preventing or treating COVID-19 diseases, comprising an organic solvent extract of Justicia procumbens as an effective ingredient, a pharmaceutical composition for preventing or treating COVID-19 diseases, comprising justicidin-A as an effective ingredient, a pharmaceutical composition for preventing or treating COVID-19 diseases, comprising justicidin-B as an effective ingredient, or a pharmaceutical composition for preventing or treating COVID-19 diseases, comprising 6′ hydroxyl justicidin-B as an effective ingredient, and a food composition thereof for preventing or ameliorating COVID-19 diseases. According to the present invention, an anhydrous ethanol extract of Justicia procumbens, justicidin-A, justicidin-B, and 6′ hydroxyl justicidin-B effectively inhibit SARS-CoV-2 virus, and thus may effectively prevent, treat, or ameliorate diseases caused by SARS-CoV-2 virus.

A method of increasing apparent total tract digestibility and retention of calcium and phosphorus in a pig is provided. The method includes administering to the pig an effective amount of a vitamin D composition comprising at least one vitamin D compound. Related compositions are also provided.

A method of increasing apparent total tract digestibility and retention of calcium and phosphorus in a pig is provided. The method includes administering to the pig an effective amount of a vitamin D composition comprising at least one vitamin D compound. Related compositions are also provided.

A synthetic nutritional composition comprising a vitamin for use to promote, support or optimise de novo myelination, in particular the de novo myelination trajectory, and/or brain structure, and/or brain connectivity, and/or intellectual potential and/or cognitive potential and/or learning potential and/or cognitive functioning in a subject, in particular a formula fed subject.

A synthetic nutritional composition comprising a vitamin for use to promote, support or optimise de novo myelination, in particular the de novo myelination trajectory, and/or brain structure, and/or brain connectivity, and/or intellectual potential and/or cognitive potential and/or learning potential and/or cognitive functioning in a subject, in particular a formula fed subject.

A non-micellar mineral-protein complex including an exogenously added mineral and a protein, where the mineral-protein complex is soluble in a solution at a physiological pH between 6.6 to 6.9 and the complex includes exogenous phosphorus.

A non-micellar mineral-protein complex including an exogenously added mineral and a protein, where the mineral-protein complex is soluble in a solution at a physiological pH between 6.6 to 6.9 and the complex includes exogenous phosphorus.